



Title	Endothelial dysfunction: A strategic target in the treatment of hypertension?
Author(s)	Tang, EHC; Vanhoutte, PM
Citation	Pflugers Archiv European Journal Of Physiology, 2010, v. 459 n. 6, p. 995-1004
Issued Date	2010
URL	http://hdl.handle.net/10722/139591
Rights	The original publication is available at www.springerlink.com

1
3
2

4 **Endothelial dysfunction: a strategic target in the treatment**
 5 **of hypertension?**

6 **Eva H. C. Tang · Paul M. Vanhoutte**

7 Received: 14 December 2009 / Revised: 6 January 2010 / Accepted: 8 January 2010
 8 © Springer-Verlag 2010

9 **Abstract** Endothelial dysfunction is a common feature of
 10 hypertension, and it results from the imbalanced release of
 11 endothelium-derived relaxing factors (EDRFs; in particular,
 12 nitric oxide) and endothelium-derived contracting factors
 13 (EDCFs; angiotensin II, endothelins, uridine adenosine
 14 tetraphosphate, and cyclooxygenase-derived EDCFs). Thus,
 15 drugs that increase EDRFs (using direct nitric oxide
 16 releasing compounds, tetrahydrobiopterin, or L-arginine
 17 supplementation) or decrease EDCF release or actions
 18 (using cyclooxygenase inhibitor or thromboxane A₂/prosta-
 19 noid receptor antagonists) would prevent the dysfunction.
 20 Many conventional antihypertensive drugs, including
 21 angiotensin-converting enzyme inhibitors, calcium channel
 22 blockers, and third-generation β-blockers, possess the
 23 ability to reverse endothelial dysfunction. Their use is
 24 attractive, as they can address arterial blood pressure and
 25 vascular tone simultaneously. The severity of endothelial
 26 dysfunction correlates with the development of coronary
 27 artery disease and predicts future cardiovascular events.
 28 Thus, endothelial dysfunction needs to be considered as a
 29 strategic target in the treatment of hypertension.
 30

Keywords Endothelium · Prostaglandin · Contraction · 31
 Free radical · Hypertensive rats 32

Introduction 33

The endothelium, the thin layer of cells that lines the inter- 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62

Endothelial dysfunction has been demonstrated both in 56
 57
 58
 59
 60
 61
 62

E. H. C. Tang (✉)
 Division of Cardiovascular Medicine,
 Brigham and Women's Hospital, Harvard Medical School,
 77 Ave Louis Pasteur, NRB741,
 Boston, MA 02115, USA
 e-mail: htang@rics.bwh.harvard.edu

P. M. Vanhoutte
 Department Pharmacology and Pharmacy,
 Li Ka Shing Faculty of Medicine, University of Hong Kong,
 Hong Kong, China

P. M. Vanhoutte
 Department BIN Fusion Technology,
 Chonbuk National University,
 Jeonju, Korea




Fig. 1 In healthy arteries, a normal vascular tone is maintained by the balanced release of EDRF and EDCF. This balance is tipped in hypertensive arteries with an increase in the release of EDCF and a decrease in the release of EDRF, favoring contractions. *EC* endothelial cell, *SMC* smooth muscle cell

by decreased forearm blood flow responses to endothelium-dependent vasodilator agonists, such as acetylcholine and bradykinin [15, 16], or by an increase in vasoconstrictor response to locally administered nitric oxide synthase inhibitors [17].

Endothelium-derived relaxing factors

The endothelium produces a range of EDRFs, the most significant and well-characterized of which is NO. But prostacyclin and endothelium-derived hyperpolarizing factors are also important endothelium-derived vasodilator signals, with the latter prominently contributing to endothelium-dependent relaxations in resistance arteries [18]. The majority of studies on endothelial dysfunction have concentrated on the mechanisms underlying the decreased bioavailability of NO. This decrease may result from a decrease in NO production, from a decrease in activation of guanylyl cyclase, and/or an increase in NO degradation (Fig. 2). A decrease in NO production may result from a deficiency in substrates and cofactors for NO synthases (NOS), such as L-arginine or tetrahydrobiopterin (BH₄) [13, 19]; from a decreased expression and presence of endothelial NOS (eNOS) [20]; from a decreased activation of NOS, such as phosphorylation of the enzyme

or interactions with proteins (e.g., heat shock protein 90 or calmodulin) [20]; or from an increased presence of endogenous inhibitors of NOS, asymmetric dimethyl arginine in particular [21] (Fig. 2). An increase in NO degradation can result from the binding of NO to molecules such as hemoglobin and albumin, or from increased inactivation of NO by its interaction with superoxide anions [22]—a reaction which leads to the production of peroxynitrite, a toxic vascular oxidant that further contributes to vasoconstriction and vascular injury (Fig. 2). Animal and clinical studies indicate that hypertension is associated with an increase in the production of reactive oxygen species (ROS), together with a decreased level of endogenous antioxidants [23–25]. The ability of vitamin C to restore NO production and improve endothelial function in essential hypertensive patients suggests a role of oxidative stress in endothelial dysfunction in humans [25].

Endothelium-derived contracting factors

The endothelial cells can produce several EDCFs, including angiotensin II, endothelin-1, dinucleotide uridine adenosine tetraphosphate (UP₄A), cyclooxygenase (COX)-derived prostanoids, and ROS [5, 26]. When these endothelium-derived vasoconstrictors are overproduced, such as in hypertension or diabetes, they oppose the vasodilator effects of the EDRFs, exacerbating endothelial dysfunction.


Angiotensin II

Angiotensin I is metabolized into angiotensin II by endothelial angiotensin-converting enzyme (ACE). Angiotensin II can activate angiotensin receptors and trigger an increase in cytosolic calcium to mediate contractions [27]. In addition to causing vasoconstriction, angiotensin II can enhance the production of ROS—predominately through the activation of membrane-bound nicotinamide adenine dinucleotide and nicotinamide adenine dinucleotide phosphate oxidases—and thus, impairs NO bioavailability [28]. Furthermore, angiotensin II can directly stimulate the production and release of endothelin-1 and thus aggravate endothelial dysfunction [29].

Endothelin-1

There are three isoforms of endothelin (identified as ET-1, ET-2, and ET-3) that activate two subtypes of receptors (ET_A and ET_B) [30]. ET_A and ET_B receptors are found in the vascular smooth muscle and are coupled to a G_q-protein that leads to IP₃ formation [30]. IP₃ stimulates calcium release

Fig. 2 Decreased bioavailability of nitric oxide may result from a decrease in NO production, an increase in NO degradation, or a decrease in the activation of guanylyl cyclase. Decreased NO production may result from deficiency in substrates and cofactors for nitric oxide synthase (NOS), decreased expression of NOS, decreased activation of NOS, or an increase in endogenous inhibitors of NOS. An increase in NO degradation can result from the binding of NO to molecules such as superoxide anions, hemoglobin, and albumin. *ADMA* asymmetric dimethyl arginine, *BH₄* tetrahydrobiopterin, *EC* endothelial cell, *hsp90* heat shock protein 90, *NOS* nitric oxide synthase, *O₂*, *ONOO⁻* peroxynitrite, *P* phosphorylation, *SMC* smooth muscle cell



130 from the sarcoplasmic reticulum, which contributes to the
 131 contraction of the vascular smooth muscle [30]. Because of
 132 its powerful vasoconstrictor properties, and the retention of
 133 sodium that it causes, endothelin-1 (the main isoform
 134 produced by endothelial cells) increases arterial blood
 135 pressure. ET_B receptors are primarily located on endothelial
 136 cells, and when stimulated, they increase the release of NO
 137 and augment natriuresis and diuresis, thus lowering blood
 138 pressure [31]. The distribution of endothelin receptors on
 139 endothelial and smooth muscle cells helps to explain the
 140 phenomenon that systemic administration of endothelin-1
 141 causes an initial transient vasodilatation (endothelial ET_B
 142 activation) and hypotension, followed by prolonged vaso-
 143 constriction and hypertension (ET_A and ET_B activation of
 144 vascular smooth muscle). Endothelin-1 can also induce the
 145 secondary release of cyclooxygenase-dependent EDCFs
 146 (presumably endoperoxides and thromboxane A₂) that cause
 147 the activation of thromboxane A₂/prostanoid (TP) receptors
 148 of vascular smooth muscle [32–34].

149 **Uridine adenosine tetraphosphate**

150 UP₄A is a non-peptidic dinucleotide endothelium-derived
 151 vasoconstrictor that is assumed to play a role in the
 152 regulation of vascular tone [35]. UP₄A possesses both purine
 153 and pyrimidine moieties, and the contraction that it causes
 154 is mediated predominately through P2X1, and probably also
 155 through P2Y2 and P2Y4 purinoceptors. UP₄A is released
 156 from the endothelium in response to acetylcholine,

endothelin-1, the calcium ionophore A23187, adenosine, 157
 and uridine triphosphate [35]. The role of UP₄A in the 158
 pathogenesis of hypertension is yet to be determined. 159

160 **COX-derived EDCFs**

161 The importance of COX-derived vasoconstrictor prostanoids 162
 has gained significant recognition in the past decade. The 163
 production of endothelium-derived prostanoids is augmented 164
 in arteries with regenerated endothelium [36, 37], and in 165
 normotensive aging and hypertensive arteries [5, 7, 9, 38]. 166
 The endothelium of the renal arteries of healthy rats also 167
 releases EDCF, suggesting that it may play a role in the 168
 regulation of basal tone in this artery, and not only during 169
 agonist-induced stimulated release [39, 40]. Studies in 170
 humans show that the acetylcholine-induced vasodilatation 171
 is diminished in conductance and resistance vessels of patients 172
 with hypertension. In these hypertensive patients, intra-arterial 173
 administration of the COX inhibitor indomethacin improved 174
 the vasodilator response to acetylcholine [41, 42], suggesting 175
 that the production of COX-derived EDCF contributes to the 176
 onset of endothelial dysfunction in human hypertension.

177 **Mechanisms underlying the production of COX-derived**
 178 **EDCFs**

179 In brief, the chain of events leading to endothelium-
 180 dependent contractions requires an abnormal increase in

181 intracellular calcium in the endothelial cells [5, 26]. The
 182 rise in calcium activates phospholipase A₂ to release
 183 arachidonic acid from the cell membrane phospholipids.
 184 Then COX breaks down arachidonic acid to form
 185 prostanoids that activate TP receptors located in the
 186 vascular smooth muscle, resulting in contraction [5, 26].
 187 During the production of prostanoids, COX simultaneously
 188 produces ROS, which can subsequently stimulate COX
 189 within the smooth muscle and produce more prostanoids
 190 [5, 26], thus amplifying the TP receptor-mediated re-
 191 sponse (Fig. 3).

192 Calcium overload


193 An abnormal, high accumulation of intracellular calcium in
 194 endothelial cells is critical and triggers the production of
 195 COX-derived EDCFs [43] (Fig. 3). Stimulation with acetyl-
 196 choline results in calcium overload in the aortic endothelial
 197 cells of SHR, but not in normotensive Wistar Kyoto rats
 198 (WKY), signifying dysfunction of calcium handling in the
 199 hypertensive strain [43]. When calcium overload is mimicked
 200 in WKY arteries using calcium-increasing agents (such as the
 201 calcium ionophore A23187 or cyclopiazonic acid),
 202 endothelium-dependent contractions are evoked despite the
 203 normal arterial blood pressure of the animals. Nonetheless,
 204 the amplitude of the contraction remains larger in SHR than
 205 in WKY [43]. This is explained best by the increased
 206 expression of COX and prostanoid synthases, a greater

207 release of prostanoids, as well as a hyper-responsiveness of
 208 the TP receptors in the aortas of SHR than in that of WKY
 209 [5, 44–46]. Hence, all these downstream modifications are
 210 not a prerequisite for the development of endothelium-
 211 dependent contractions, but their presence amplifies the
 212 response.

213 COX activity

214 The activity of COX is required for the generation of
 215 vasoconstrictor prostanoids. Two isoforms of COX, a
 216 constitutive form (COX1) and an inducible form (COX2),
 217 have been cloned and characterized [47]. Yet COX1—
 218 termed as the constitutive isoform—can be over-expressed
 219 under certain conditions, such as increases in shear stress
 220 [47]. Inflammation is the most common cause for the up-
 221 regulation of COX2 [47]. Multiple studies using arteries
 222 from mice and rats have confirmed that COX1 is the
 223 primary isoform involved in endothelium-dependent con-
 224 tractions. For example, endothelium-dependent contractions
 225 are abolished by selective COX1 inhibitors, but are
 226 relatively insensitive to selective COX2 inhibitors [9, 48].
 227 Furthermore, endothelium-dependent contractions occur in
 228 the aortas of wild-type and COX2^{-/-} knockout mice, but
 229 not in those of COX1^{-/-} knockout mice [49]. Later studies
 230 using hamster aortas [50] and aging rats [51], however,
 231 showed that COX2 can contribute equally to the contraction
 232 when present or induced in the endothelial cells.

Fig. 3 Endothelium-dependent contraction has two components: the generation of prostaglandins and ROS. A rise in calcium activates phospholipase A₂ (PLA₂) to release arachidonic acid, which is subsequently metabolized by cyclooxygenase (COX) to form endoperoxides and various prostaglandins that activate TP receptors located at the vascular smooth muscle. COX also produces ROS, which diffuses or possibly transmigrates via gap junctions and stimulates COX within the smooth muscle, producing more prostanoids and amplifying TP receptor-mediated contractions. ADP adenosine diphosphate, m muscarinic receptors, P purinergic receptors, PGE₂ prostaglandin E₂, PGF_{2α} prostaglandin F_{2α}; PGI₂ prostacyclin, ROS reactive oxygen species, TXA₂ thromboxane A₂



233	Production of prostanoids	
234	The immediate products of COX are the endoperoxides,	285
235	which themselves function as vasoconstrictors by binding	286
236	to TP receptors [45]. Endoperoxides are further transformed	287
237	into prostacyclin, thromboxane A ₂ , prostaglandin E ₂ ,	288
238	prostaglandin F _{2α} , and prostaglandin D ₂ by their respective	
239	prostanoid synthases (Fig. 3). Prostacyclin synthase is by	
240	far the most abundant prostanoid synthase expressed in the	
241	endothelium [52]. Its expression is augmented in the aorta	
242	of SHR compared with that of WKY [52, 53], suggesting	
243	that chronic hypertension induces the protein. In line with	
244	this observation, there is an exaggerated release of	
245	prostacyclin in the aorta of the hypertensive rat [46, 54,	
246	55]. Since this classical vasodilator prostanoid does not	
247	mediate relaxation in this artery, it instead evokes contrac-	
248	tion through activation of TP receptors at high concen-	
249	trations [44]. In response to acetylcholine, prostacyclin and	
250	endoperoxides are the key mediators of endothelium-	
251	dependent contractions in the rat aorta [5, 44]. Whether or	
252	not prostacyclin plays a detrimental role as EDCF in other	
253	animal models or in humans remains to be demonstrated.	
254	Under certain pathological conditions involving en-	
255	hanced oxidative stress, ROS interacts with NO to form	
256	peroxynitrite [22], which can significantly inhibit the	
257	activity of prostacyclin synthase by tyrosine nitration of	
258	the enzyme [56, 57]. Under such circumstances, there is a	
259	marked compensatory production of prostaglandin E ₂ and	
260	prostaglandin F _{2α} , leading to greater importance of these	
261	two prostanoids [46, 56, 58]. In the hamster aorta and in	
262	human renal arteries, there is a high expression of COX2	
263	and a prominent release of prostaglandin F _{2α} , indicating the	
264	importance of this prostanoid as the EDCF in these arteries	
265	[50]. Likewise, prostaglandin F _{2α} is the major EDCF	
266	released from re-endothelized femoral rat arteries [36].	
267	When endothelium-dependent contractions are evoked	
268	by the calcium ionophore A23187 or adenosine diphos-	
269	phate (ADP) in the aorta of SHR, the response is partly	
270	sensitive to inhibitors of thromboxane synthase [54, 55,	
271	59], implying the involvement of thromboxane A ₂ . The	
272	mRNA expression of thromboxane synthase is enhanced in	
273	the aorta of SHR compared to WKY [52]. Direct chemical	
274	detection with immunoassays has revealed that A23187 and	
275	ADP stimulate the release of thromboxane A ₂ and	
276	endoperoxides [46, 54, 55], suggesting that these prosta-	
277	noids are the key mediators of endothelium-dependent	
278	contraction during exposure to these agonists.	
279	On the whole, there is a marked heterogeneity in the	
280	formation of EDCF. The precise chemical identity of EDCF	
281	varies depending on the stimulus, the vascular bed, the age,	
282	and the physiopathological condition of the donor animal.	
283	Thus, prostacyclin, thromboxane A ₂ , prostaglandin E ₂ ,	
284	prostaglandin F _{2α} , and ROS all have been proposed as	
	COX-derived EDCF. It is important to keep in mind that	285
	endothelium-dependent contractions are unlikely to be due	286
	a single substance, but rather likely are evoked by a mixture	287
	of these endothelium-derived products (Fig. 3).	288
	The involvement of TP receptors	289
	Prostanoid receptors are classified into five discrete types	290
	based on their sensitivity to the five naturally occurring	291
	prostanoids: prostacyclin I ₂ , thromboxane A ₂ , prostaglandin	292
	D ₂ , prostaglandin E ₂ , and prostaglandin F _{2α} . They are	293
	termed P receptors—IP, TP, DP, EP, and FP—with the	294
	preceding letter indicating the prostanoid to which they are	295
	the most sensitive. The effectiveness of TP receptor	296
	inhibitors in abolishing endothelium-dependent contrac-	297
	tions pinpoints the involvement of this prostanoid receptor	298
	subtype in the response [48, 60–62]. Although thrombox-	299
	ane A ₂ is the most potent agonist towards TP receptors, it is	300
	not its exclusive ligand. All other prostanoids can bind to	301
	TP receptors and mediate contraction, but with varying	302
	potency. The mRNA and protein expression of TP receptors	303
	does not differ in the aortas of WKY and SHR, indicating	304
	that their expression level is not altered by the hypertensive	305
	process [52, 63]. However, the vascular smooth muscle of	306
	the SHR aorta exhibits a greater responsiveness than that of	307
	the WKY to the constrictor effect of endoperoxides acting	308
	at TP receptors [45]. An involvement of other prostanoid	309
	receptors in endothelium-dependent contractions has been	310
	suggested [63–65], but non-TP receptor endothelium-	311
	dependent component appears to constitute a small part of	312
	the full response.	313
	A separate ROS component	314
	During the production of prostanoids by endothelial COX,	315
	ROS are formed simultaneously. These COX-derived ROS	316
	can act as vasoconstrictors [43, 62]. Thus, COX-derived	317
	EDCF-mediated contractions can be attributed to two	318
	components—prostanoids or ROS [5] (Fig. 3). The possible	319
	existence of a separate ROS component in endothelium-	320
	dependent contractions is strengthened by the following	321
	observations: First, that the generation of ROS by xanthine	322
	plus xanthine oxidase in the extracellular bathing fluid	323
	evokes a contraction in the aorta without endothelium that	324
	requires the activity of COX and stimulation of TP	325
	receptors [62, 66], suggesting that endothelium-derived	326
	ROS could stimulate COX in the vascular smooth muscle	327
	with resulting prostanoid production, causing more TP	328
	receptor-mediated contraction. Second, the direct applica-	329
	tion of hydrogen peroxide, but not that of superoxide	330
	anions or hydroxyl radicals, triggers contractions in the rat	331

332 aorta that are sensitive to cyclooxygenase inhibitors and TP
 333 receptor antagonists [66–69], suggesting that hydrogen
 334 peroxide is the mediator responsible for the ROS compo-
 335 nent of endothelium-dependent contraction. Myoendothe-
 336 lial gap junctions may facilitate the transfer of ROS from
 337 endothelial cells to smooth muscle cells [70]. In the aorta of
 338 the SHR, both the prostanoid and ROS component appear
 339 to contribute equally to the final endothelium-dependent
 340 contractions, as antioxidants only partly reduce the re-
 341 sponse [62]. By contrast, in the canine basilar artery,
 342 endothelium-dependent contractions are fully prevented by
 343 superoxide dismutase plus catalase [71], indicating that the
 344 response is dominated by the endothelial ROS component.

345 **Therapeutic interventions to improve endothelial**
 346 **function in hypertension**

347 Considering the marked endothelial dysfunction in hyper-
 348 tension and since its severity correlates with the develop-
 349 ment of coronary artery disease and predicts future
 350 cardiovascular events [72], this dysfunction has to be
 351 considered as a central target in the treatment of hyperten-
 352 sion. Theoretically, drugs targeted to increase the release of
 353 EDRF (and in particular, NO), and drugs that decrease the
 354 production or action of EDCF, should reduce endothelial
 355 dysfunction.

356 Improving NO production

357 Direct NO releasing compounds, such as nitroglycerin, are
 358 effective vasodilators. However, continuous administration
 359 comprises a clinical problem due to the desensitization of
 360 the target enzyme guanylyl cyclase, leading to cross-
 361 tolerance to other endothelium-dependent vasodilators
 362 [73]. Other concerns involve the ability of nitroglycerin to
 363 increase ROS indirectly [74].

364 Acute supplementation with BH₄, an essential cofactor
 365 of NOS, improves endothelial dysfunction by increasing
 366 NO and reducing ROS in many experimental animal studies
 367 [75]. But a clinical trial of the effects of BH₄ on arterial
 368 blood pressure in subjects with poorly controlled systemic
 369 hypertension has been terminated for lack of significant
 370 beneficial effect [76]. By contrast, positive results have
 371 been reported with the use of BH₄ to treat endothelial
 372 dysfunction in patients with sickle-cell disease [76]. The
 373 dissimilar results in these clinical trials highlight the
 374 importance of fully addressing basic questions about
 375 the mechanism of endothelial regulation that will be critical
 376 in the design of BH₄-based therapies.

377 Endogenous NO formation is largely dependent on the
 378 extracellular concentrations of its substrate, L-arginine.
 379 Supplementation of L-arginine leads to a measurable

decline in blood pressure and improved endothelial func- 380
 tions in experimental animals and in hypertensive patients 381
 [77, 78]. Most L-arginine studies to date have used high 382
 daily doses, due to the pharmacokinetics of oral L-arginine, 383
 which reaches its highest concentration in the blood within 384
 an hour and then diminishes quickly [77]. The use of 385
 sustained-release L-arginine products in hypertensive 386
 patients shows promising signs of improving endothelial 387
 function [79]. 388

When arteries are exposed to NO, whether released from 389
 the endothelial cells or added exogenously, this causes a 390
 long-term inhibition of endothelium-dependent contractions 391
 [80–83]. This implies a suppressed occurrence of EDCF- 392
 mediated contractions under conditions where there is an 393
 adequate release of NO. Thus, NO-enhancing agents not 394
 only will enhance vasodilatation, but also will hamper the 395
 occurrence of endothelium-dependent contractions. 396

Reducing arterial blood pressure 397

Antihypertensive treatments—such as ACE inhibitors, 398
 calcium channel blockers, and third generation β- 399
 blockers—reverse endothelial dysfunction in experimental 400
 animals and in hypertensive patients [84, 85]. Several 401
 effects of ACE inhibitors enhance NO release and 402
 bioactivity, including preventing the breakdown of endog- 403
 enous bradykinin (a potent NO releaser) [85]. ACE 404
 inhibitors also protect NO bioavailability [85]. The 405
 beneficial effect of calcium channel blockers on endothe- 406
 lial dysfunction can be attributed to their ability to reduce 407
 calcium entry through voltage-dependent channels of the 408
 vascular muscle cells, thereby dilating large conduit and 409
 resistance arteries [86]. In addition, drugs such as amlodi- 410
 pine activate eNOS to release more NO [87, 88]. Other 411
 calcium channel blockers, such as lacidipine, possess 412
 antioxidant properties [89], while third-generation β- 413
 blockers such as carvedilol and nebivolol, in addition to 414
 their adrenergic blocking characteristics, substantially im- 415
 prove endothelial dysfunction through their strong stimula- 416
 tory effect on the activity of endothelial NOS and their 417
 antioxidative properties [90]. Blood pressure reduction per se 418
 does not guarantee improvement in endothelial dysfunction. 419
 Other antihypertensive drugs, such as conventional β- 420
 adrenergic blockers, reduce arterial blood pressure but fail 421
 to restore normal endothelial function [85]. 422

Preventing EDCF-mediated responses 423

Because prostacyclin is one of the main mediators of 424
 endothelium-dependent contractions in the response of 425
 acetylcholine, inhibition of its production may result in 426
 the improvement of endothelial function. But prostacy- 427
 clin also is beneficial to the vascular system because of 428

429 its ability to prevent aggregation of platelets and avoid
 430 thrombosis [91]. In addition, inhibition of prostacyclin
 431 synthase results in the build-up of endoperoxides (which
 432 by themselves activate TP receptors) and the shunting
 433 of the latter to other synthases, which produce more
 434 potent vasoconstrictor prostanoids [46, 54, 55]. There-
 435 fore, selective inhibition of prostacyclin synthase would
 436 not reduce the occurrence of unwanted endothelium-
 437 dependent contractions, but rather would result in ampli-
 438 fied worsening of the vascular complications. In the SHR
 439 aorta, thromboxane A₂, and endoperoxides are the main
 440 EDCF in response to A23187 and adenosine diphosphate
 441 [44, 54, 55]. In the aorta of the hamster, in response to
 442 acetylcholine, the main EDCF is prostaglandin F_{2α} [50].
 443 Thus, the contribution of various prostaglandins released
 444 during endothelium-dependent contractions varies
 445 depending on the stimulus, the artery, the species, and
 446 the disease state of the donor. It therefore appears more
 447 desirable to design drugs that target either upstream or
 448 downstream of the EDCF cascade, rather than individual
 449 prostanoid synthases, to alleviate EDCF-mediated endo-
 450 thelial dysfunction.

451 Depending on the availability of the enzyme, both
 452 COX1 and COX2 can contribute to endothelium-
 453 dependent contractions. Thus, the use of selective drugs
 454 targeting a specific isoform of COX is not the rationale of
 455 choice to inhibit endothelium-dependent contractions in
 456 hypertension. Moreover, the use of non-selective COX
 457 inhibitors are linked with multiple adverse effects, includ-
 458 ing peptic ulceration and dyspepsia, while selective COX-2
 459 inhibition increases the risk of myocardial infarction,
 460 thrombosis, and stroke [92].

461 EDCFs ultimately converge to activate TP receptors [48,
 462 60–62]. Although other prostanoid receptors may contrib-
 463 ute [63–65], it seems—at least from data obtained in animal
 464 studies—that TP receptors are the dominant receptor
 465 subtype involved. The TP receptor blocker terutroban
 466 improves endothelial function in patients with coronary
 467 disease [93], which illustrates the role of vasoconstrictor
 468 prostanoids in human endothelial dysfunction. Thus, selec-
 469 tive TP receptor antagonists may be the most logical
 470 therapeutic tools to intervene with endothelium-dependent
 471 contractions in hypertension. Epoxyeicosatrienoic and
 472 dihydroxyeicosatrienoic acids function as endogenous TP-
 473 receptor antagonists and induce vasodilatation [94], sug-
 474 gesting their use as novel TP receptor inhibitors. Synthetic
 475 TP receptor blockers (such as terutroban) effectively
 476 prevent endothelium-dependent contraction in numerous
 477 hypertensive experimental animal models [7, 48, 51, 60–
 478 62]. The prospective use of TP-receptor antagonists in
 479 correcting the consequences of the imbalanced release of
 480 endothelium-derived vasoactive substances in hypertensive
 481 patients deserves further exploration.

Conclusion

482
 483 The endothelium is one of the major target organs that are
 484 damaged by high blood pressure. Chronic elevation in blood
 485 pressure accelerates the turnover of endothelial cells, causing
 486 them to age prematurely. The regenerated endothelium has an
 487 impaired ability to release EDRF and favors the occurrence of
 488 endothelium-dependent contractions. Endothelial dysfunction
 489 triggers a chain of undesired responses, including increased
 490 platelet aggregation, expression of adhesion molecules, and
 491 vascular muscle growth—ultimately leading to thrombosis,
 492 inflammation, vascular remodeling, and atherosclerosis. En-
 493 dothelial dysfunction therefore should be considered as a
 494 central target in the treatment of hypertension. Mechanisms
 495 that increase EDRF or decrease the release/bioavailability
 496 action of EDCF are promising drug targets to mitigate the
 497 damage caused by endothelial dysfunction.

References

498
 499 1. Félétou M, Vanhoutte PM (2006) Endothelial dysfunction: a
 500 multifaceted disorder (The Wiggers Award Lecture). *Am J Physiol*
 501 *Heart Circ Physiol* 291:H985–H1002
 502 2. Susic D (1997) Hypertension, aging, and atherosclerosis. The
 503 endothelial interface. *Med Clin North Am* 81:1231–1240
 504 3. Flavahan NA, Vanhoutte PM (1990) G-proteins and endothelial
 505 responses. *Blood Vessels* 27:218–229
 506 4. Shibano T, Codina J, Birnbaumer L, Vanhoutte PM (1994)
 507 Pertussis toxin-sensitive G proteins in regenerated endothelial
 508 cells of porcine coronary artery. *Am J Physiol* 267:H979–H981
 509 5. Tang EH, Vanhoutte PM (2009) Prostanoids and reactive oxygen
 510 species: team players in endothelium-dependent contractions.
 511 *Pharmacol Ther* 122:140–149
 512 6. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M (2009)
 513 Endothelial dysfunction and vascular disease. *Acta Physiol (Oxf)*
 514 196:193–222
 515 7. Michel FS, Man GS, Man RY, Vanhoutte PM (2008) Hyperten-
 516 sion and the absence of EDHF-mediated responses favour
 517 endothelium-dependent contractions in renal arteries of the rat.
 518 *Br J Pharmacol* 155:217–226
 519 8. Sekiguchi F, Nakahira T, Kawata K, Sunano S (2002) Responses
 520 to endothelium-derived factors and their interaction in mesenteric
 521 arteries from Wistar Kyoto and stroke-prone spontaneously
 522 hypertensive rats. *Clin Exp Pharmacol Physiol* 29:1066–1074
 523 9. Yang D, Gluais P, Zhang JN, Vanhoutte PM, Félétou M (2004)
 524 Endothelium-dependent contractions to acetylcholine, ATP and
 525 the calcium ionophore A 23187 in aortas from spontaneously
 526 hypertensive and normotensive rats. *Fundam Clin Pharmacol*
 527 18:321–326
 528 10. Lee J, Choi KC, Yeum CH, Kim W, Yoo K, Park JW, Yoon PJ
 529 (1995) Impairment of endothelium-dependent vasorelaxation in
 530 chronic two-kidney, one-clip hypertensive rats. *Nephrol Dial*
 531 *Transplant* 10:619–623
 532 11. Stankevicius E, Martinez AC, Mulvany MJ, Simonsen U (2002)
 533 Blunted acetylcholine relaxation and nitric oxide release in arteries
 534 from renal hypertensive rats. *J Hypertens* 20:1571–1579
 535 12. Cordellini S (1999) Endothelial dysfunction in DOCA-salt
 536 hypertension: possible involvement of prostaglandin endoperox-
 537 ides. *Gen Pharmacol* 32:315–320

538 13. Zhou MS, Kosaka H, Tian RX, Abe Y, Chen QH, Yoneyama H, Yamamoto A, Zhang L (2001) L-Arginine improves endothelial function in renal artery of hypertensive Dahl rats. *J Hypertens* 19:421–429

540 14. Zhou MS, Nishida Y, Chen QH, Kosaka H (1999) Endothelium-derived contracting factor in carotid artery of hypertensive Dahl rats. *Hypertension* 34:39–43

542 15. Linder L, Kiowski W, Bühler FR, Lüscher TF (1990) Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. *Circulation* 81:1762–1767

544 16. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE (1990) Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. *N Engl J Med* 323:22–27

546 17. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA (1993) Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. *Circulation* 87:1468–1474

548 18. Félétou M, Vanhoutte PM (2006) Endothelium-derived hyperpolarizing factor: where are we now? *Arterioscler Thromb Vasc Biol* 26:1215–1225

549 19. Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T, Chayama K (2002) Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. *Am J Hypertens* 15:326–332

551 20. Sessa WC (2005) Regulation of endothelial derived nitric oxide in health and disease. *Mem Inst Oswaldo Cruz* 100:15–18

552 21. Cooke JP (2000) Does ADMA cause endothelial dysfunction? *Arterioscler Thromb Vasc Biol* 20:2032–2037

553 22. Gryglewski RJ, Palmer RM, Moncada S (1986) Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. *Nature* 320:454–456

554 23. Mehta JL, Lopez LM, Chen L, Cox OE (1994) Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. *Am J Cardiol* 74:901–905

555 24. Sagar S, Kallo IJ, Kaul N, Ganguly NK, Sharma BK (1992) Oxygen free radicals in essential hypertension. *Mol Cell Biochem* 111:103–108

556 25. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A (1998) Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. *Circulation* 97:2222–2229

557 26. Vanhoutte PM, Tang EH (2008) Endothelium-dependent contractions: when a good guy turns bad! *J Physiol* 586:5295–304

558 27. Ferder L, Inserra E, Martinez-Maldonado M (2006) Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. *Curr Hypertens Rep* 8:191–198

559 28. Zhang H, Schmeisser A, Garlichs CD, Plötze K, Damme U, Mügge A, Daniel WG (1999) Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH/NADPH-oxidases. *Cardiovasc Res* 44:215–222

560 29. Dohi Y, Hahn AW, Boulanger CM, Bühler FR, Lüscher TF (1992) Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. *Hypertension* 19:131–137

561 30. Pollock DM, Keith TL, Highsmith RF (1995) Endothelin receptors and calcium signaling. *FASEB J* 9:1196–1204

562 31. Hoffman A, Abassi ZA, Brodsky S, Ramadan R, Winaver J (2000) Mechanisms of big endothelin-1-induced diuresis and natriuresis: role of ET(B) receptors. *Hypertension* 35:732–739

563 32. Asano H, Shimizu K, Muramatsu M, Iwama Y, Toki Y, Miyazaki Y, Okumura K, Hashimoto H, Ito T (1994) Prostaglandin H₂ as an endothelium-derived contracting factor modulates endothelin-1-induced contraction. *J Hypertens* 12:383–390

564 33. Auch-Schwelk W, Vanhoutte PM (1992) Contractions to endothelin in normotensive and spontaneously hypertensive rats: role of endothelium and prostaglandins. *Blood Press* 1:45–49

565 34. Taddei S, Vanhoutte PM (1993) Role of endothelium in endothelin-evoked contractions in the rat aorta. *Hypertension* 21:9–15

566 35. Jankowski V, Tolle M, Vanholder R, Schonfelder G, van der Giet M, Henning L, Schluter H, Paul M, Zidek W, Jankowski J (2005) Uridine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor. *Nat Med* 11:223–227

567 36. Hirao A, Kondo K, Takeuchi K, Inui N, Umemura K, Ohashi K, Watanabe H (2008) Cyclooxygenase-dependent vasoconstricting factor(s) in remodelled rat femoral arteries. *Cardiovasc Res* 79:161–168

568 37. Park SJ, Lee JJ, Vanhoutte PM (1999) Endothelin-1 releases endothelium-derived endoperoxides and thromboxane A₂ in porcine coronary arteries with regenerated endothelium. *Acta Pharmacol Sin* 20:872–878

569 38. Lüscher TF, Vanhoutte PM (1986) Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. *Hypertension* 8:344–348

570 39. Gao YJ, Lee RM (2005) Hydrogen peroxide is an endothelium-dependent contracting factor in rat renal artery. *Br J Pharmacol* 146:1061–1068

571 40. Nishimura Y, Usui H, Kurahashi K, Suzuki A (1995) Endothelium-dependent contraction induced by acetylcholine in isolated rat renal arteries. *Eur J Pharmacol* 275:217–221

572 41. Taddei S, Virdis A, Mattei P, Salvetti A (1993) Vasodilation to acetylcholine in primary and secondary forms of human hypertension. *Hypertension* 21:929–933

573 42. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S (2009) Endothelium-dependent contractions and endothelial dysfunction in human hypertension. *Br J Pharmacol* 157:527–536

574 43. Tang EH, Leung FP, Huang Y, Feletou M, So KF, Man RY, Vanhoutte PM (2007) Calcium and reactive oxygen species increase in endothelial cells in response to releasers of endothelium-derived contracting factor. *Br J Pharmacol* 151:15–23

575 44. Félétou M, Verbeuren TJ, Vanhoutte PM (2009) Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors. *Br J Pharmacol* 156:563–574

576 45. Ge T, Hughes H, Junquero DC, Wu KK, Vanhoutte PM, Boulanger CM (1995) Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H₂ in the SHR aorta. *Circ Res* 76:1003–1010

577 46. Gluais P, Lonchampt M, Morrow JD, Vanhoutte PM, Feletou M (2005) Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. *Br J Pharmacol* 146:834–845

578 47. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. *FASEB J* 12:1063–1073

579 48. Yang D, Félétou M, Levens N, Zhang JN, Vanhoutte PM (2003) A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. *Hypertension* 41:143–148

580 49. Tang EH, Ku DD, Tipoe GL, Feletou M, Man RY, Vanhoutte PM (2005) Endothelium-dependent contractions occur in the aorta of wild-type and COX2^{-/-} knockout but not COX1^{-/-} knockout mice. *J Cardiovasc Pharmacol* 46:761–765

581 50. Wong SL, Leung FP, Lau CW, Au CL, Yung LM, Yao X, Chen ZY, Vanhoutte PM, Gollasch M, Huang Y (2009) Cyclooxygenase-2-derived prostaglandin F₂α mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. *Circ Res* 104:228–235

604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669

670 51. Shi Y, Man RY, Vanhoutte PM (2008) Two isoforms of cyclo- 736
671 oxygenase contribute to augmented endothelium-dependent 737
672 contractions in femoral arteries of 1-year-old rats. *Acta Pharmacol Sin* 738
673 29:185–192
674 52. Tang EH, Vanhoutte PM (2008) Gene expression changes of 739
675 prostanoid synthases in endothelial cells and prostanoid receptors 740
676 in vascular smooth muscle cells caused by aging and hyperten- 741
677 sion. *Physiol Genomics* 32:409–418
678 53. Numaguchi Y, Harada M, Osanai H, Hayashi K, Toki Y, Okumura 742
679 K, Ito T, Hayakawa T (1999) Altered gene expression of 743
680 prostacyclin synthase and prostacyclin receptor in the thoracic 744
681 aorta of spontaneously hypertensive rats. *Cardiovasc Res* 41:682– 745
682 688
683 54. Gluais P, Paysant J, Badier-Commander C, Verbeuren T, 746
684 Vanhoutte PM, Félétou M (2006) In SHR aorta, calcium 747
685 ionophore A-23187 releases prostacyclin and thromboxane A2 748
686 as endothelium-derived contracting factors. *Am J Physiol Heart* 749
687 *Circ Physiol* 291:H2255–H2264
688 55. Gluais P, Vanhoutte PM, Félétou M (2007) Mechanisms underly- 750
689 ing ATP-induced endothelium-dependent contractions in the SHR 751
690 aorta. *Eur J Pharmacol* 556:107–114
691 56. Zou MH, Leist M, Ullrich V (1999) Selective nitration of 752
692 prostacyclin synthase and defective vasorelaxation in athero- 753
693 sclerotic bovine coronary arteries. *Am J Pathol* 154:1359– 754
694 1365
695 57. Zou MH, Shi C, Cohen RA (2002) High glucose via 755
696 peroxynitrite causes tyrosine nitration and inactivation of 756
697 prostacyclin synthase that is associated with thromboxane/ 757
698 prostaglandin H(2) receptor-mediated apoptosis and adhesion 758
699 molecule expression in cultured human aortic endothelial 759
700 cells. *Diabetes* 51:198–203
701 58. Bachschmid M, Thurau S, Zou MH, Ullrich V (2003) Endothelial 760
702 cell activation by endotoxin involves superoxide/NO-mediated 761
703 nitration of prostacyclin synthase and thromboxane receptor 762
704 stimulation. *FASEB J* 17:914–916
705 59. Dai FX, Skopec J, Diederich A, Diederich D (1992) Prostaglandin 763
706 H2 and thromboxane A2 are contractile factors in intrarenal 764
707 arteries of spontaneously hypertensive rats. *Hypertension* 19:795– 765
708 798
709 60. Auch-Schwelk W, Katusic ZS, Vanhoutte PM (1990) Thrombox- 766
710 ane A₂ receptor antagonists inhibit endothelium-dependent con- 767
711 tractions. *Hypertension* 15:699–703
712 61. Kato T, Iwama Y, Okumura K, Hashimoto H, Ito T, Satake T 768
713 (1990) Prostaglandin H2 may be the endothelium-derived con- 769
714 tracting factor released by acetylcholine in the aorta of the rat. 770
715 *Hypertension* 15:475–481
716 62. Yang D, Félétou M, Boulanger CM, Wu HF, Levens N, Zhang JN, 771
717 Vanhoutte PM (2002) Oxygen-derived free radicals mediate 772
718 endothelium-dependent contractions to acetylcholine in aortas 773
719 from spontaneously hypertensive rats. *Br J Pharmacol* 136:104– 774
720 110
721 63. Tang EH, Jensen BL, Skott O, Leung GP, Feletou M, Man RY, 775
722 Vanhoutte PM (2008) The role of prostaglandin E and 776
723 thromboxane-prostanoid receptors in the response to prostaglan- 777
724 din E2 in the aorta of Wistar Kyoto rats and spontaneously 778
725 hypertensive rat. *Cardiovasc Res* 78:130–138
726 64. Rapoport RM, Williams SP (1996) Role of prostaglandins in 779
727 acetylcholine-induced contraction of aorta from spontaneously 780
728 hypertensive and Wistar-Kyoto rats. *Hypertension* 28:64–75
729 65. Shi Y, Feletou M, Ku DD, Man RY, Vanhoutte PM (2007) The 781
730 calcium ionophore A23187 induces endothelium-dependent con- 782
731 tractions in femoral arteries from rats with streptozotocin-induced 783
732 diabetes. *Br J Pharmacol* 150:624–632
733 66. Auch-Schwelk W, Katusic ZS, Vanhoutte PM (1989) Contractions 784
734 to oxygen-derived free radicals are augmented in aorta of the 785
735 spontaneously hypertensive rat. *Hypertension* 13:859–864

67. Li J, Li W, Li W, Altura BT, Altura BM (2004) Mechanisms of 736
hydroxyl radical-induced contraction of rat aorta. *Eur J Pharmacol* 737
499:171–178
68. Rodriguez-Martinez MA, Garcia-Cohen EC, Baena AB, Gonzalez 738
R, Salas M, Marin J (1998) Contractile responses elicited by 739
hydrogen peroxide in aorta from normotensive and hypertensive 740
rats. Endothelial modulation and mechanism involved. *Br J* 741
Pharmacol 125:1329–1335
69. Yang Z, Zheng T, Zhang A, Altura BT, Altura BM (1998) 742
Mechanisms of hydrogen peroxide-induced contraction of rat 743
aorta. *Eur J Pharmacol* 344:169–181
70. Tang EH, Vanhoutte PM (2008) Gap junction inhibitors reduce 744
endothelium-dependent contractions in the aorta of spontaneously 745
hypertensive rats. *J Pharmacol Exp Ther* 327:148–153
71. Katusic ZS, Vanhoutte PM (1989) Superoxide anion is an 746
endothelium-derived contracting factor. *Am J Physiol* 257:H33– 747
H37
72. Neunteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher 748
S, Glogar D, Bauer P, Weidinger F (1997) Systemic endothelial 749
dysfunction is related to the extent and severity of coronary artery 750
disease. *Atherosclerosis* 129:111–118
73. Sayed N, Kim DD, Fioramonti X, Iwashita T, Durán WN, Beuve 751
A (2008) Nitroglycerin-induced S-nitrosylation and desensitiza- 752
tion of soluble guanylyl cyclase contribute to nitrate tolerance. 753
Circ Res 103:606–614
74. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, 754
Ullrich V, Mülsch A, Schulz E, Keaney JF Jr, Stamler JS, Münzel 755
T (2004) Central role of mitochondrial aldehyde dehydrogenase 756
and reactive oxygen species in nitroglycerin tolerance and cross- 757
tolerance. *J Clin Invest* 113:482–489
75. Katusic ZS (2001) Vascular endothelial dysfunction: does tetrahy- 758
drobiopterin play a role? *Am J Physiol Heart Circ Physiol* 281: 759
H981–H986
76. Vásquez-Vivar J (2009) Tetrahydrobiopterin, superoxide, and 760
vascular dysfunction. *Free Radic Biol Med* 47:1108–1119
77. Gokce N (2004) L-Arginine and hypertension. *J Nutr* 134:2807S– 761
2811S
78. Lekakis JP, Papathanassiou S, Papaioannou TG, Papamichael CM, 762
Zakopoulos N, Kotsis V, Dagher AG, Stamatiopoulos K, Proto- 763
gerou A, Stamatiopoulos SF (2002) Oral L-arginine improves 764
endothelial dysfunction in patients with essential hypertension. *Int* 765
J Cardiol 86:317–323
79. Miller AL (2006) The effects of sustained-release L-arginine 766
formulation on blood pressure and vascular compliance in 29 767
healthy individuals. *Altern Med Rev* 11:23–29
80. Auch-Schwelk W, Katusic ZS, Vanhoutte PM (1992) Nitric oxide 768
inactivates endothelium-derived contracting factor in the rat aorta. 769
Hypertension 19:442–445
81. Feletou M, Tang EH, Vanhoutte PM (2008) Nitric oxide the 770
gatekeeper of endothelial vasomotor control. *Front Biosci* 13:4198–4217
82. Tang EH, Feletou M, Huang Y, Man RY, Vanhoutte PM (2005) 771
Acetylcholine and sodium nitroprusside cause long-term inhibi- 772
tion of EDCF-mediated contractions. *Am J Physiol Heart Circ* 773
Physiol 289:H2434–2440
83. Yang D, Gluais P, Zhang JN, Vanhoutte PM, Félétou M (2004) 774
Nitric oxide and inactivation of the endothelium-dependent 775
contracting factor released by acetylcholine in spontaneously 776
hypertensive rat. *J Cardiovasc Pharmacol* 43:815–820
84. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, 777
Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, 778
Haber HE, Uprichard AC, Pepine CJ, Pitt B (1996) Angiotensin- 779
converting enzyme inhibition with quinapril improves endothelial 780
vasomotor dysfunction in patients with coronary artery disease. 781
The TREND (Trial on Reversing ENdothelial Dysfunction) Study. 782
Circulation 94:258–265

802 85. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A (2002) 820
 803 Effects of antihypertensive drugs on endothelial dysfunction: 821
 804 clinical implications. *Drugs* 62:265–284 822
 805 86. Godfraind T (2005) Antioxidant effects and the therapeutic mode 823
 806 of action of calcium channel blockers in hypertension and 824
 807 atherosclerosis. *Philos Trans R Soc Lond B Biol Sci* 360:2259– 825
 808 2272 826
 809 87. Batova S, DeWever J, Godfraind T, Balligand JL, Dessy C, Feron 827
 810 O (2006) The calcium channel blocker amlodipine promotes the 828
 811 unclamping of eNOS from caveolin in endothelial cells. *Cardio- 829
 812 vasc Res* 71:478–485 830
 813 88. Lenasi H, Kohlstedt K, Fichtlscherer B, Mülsch A, Busse R, 831
 814 Fleming I (2003) Amlodipine activates the endothelial nitric oxide 832
 815 synthase by altering phosphorylation on Ser1177 and Thr495. 833
 816 *Cardiovasc Res* 59:844–853 834
 817 89. van Amsterdam FT, Roveri A, Maiorino M, Ratti E, Ursini F 835
 818 (1992) Lacidipine: a dihydropyridine calcium antagonist with 836
 819 antioxidant activity. *Free Radic Biol Med* 12:183–187 837
 838 90. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski 820
 M, Martyniec L, Angielski S, Malinski T (2003) Third-generation 821
 beta-blockers stimulate nitric oxide release from endothelial cells 822
 through ATP efflux: a novel mechanism for antihypertensive 823
 action. *Circulation* 107:2747–2752 824
 91. Moncada S, Vane JR (1997) The role of prostacyclin in vascular 825
 tissue. *Fed Proc* 38:66–71 826
 92. Salinas G, Rangasetty UC, Uretsky BF, Birnbaum Y (2007) The 827
 cyclooxygenase 2 (COX-2) story: it's time to explain, not inflame. *J 828
 Cardiovasc Pharmacol Ther* 12:98–111 829
 93. Belhassen L, Pelle G, Dubois-Rande J, Adnot S (2003) Improved 830
 endothelial function by the thromboxane α_2 receptor antagonist 831
 S18886 in patients with coronary artery disease treated with 832
 aspirin. *J Am Coll Cardiol* 41:1198–1204 833
 94. Behm DJ, Ogbonna A, Wu C, Burns-Kurtis CL, Douglas SA (2009) 834
 Epoxyeicosatrienoic acids function as selective, endogenous antag- 835
 onists of native thromboxane receptors: identification of a novel 836
 mechanism of vasodilation. *J Pharmacol Exp Ther* 328:231–239 837

UNCORRECTED PROOF